HaTay Pharmaceutical JSC EV/EBIT
The EV/EBIT (Enterprise Value to EBIT) of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 3, 2026 is 81.91. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 63.17 — a change of 29.67% (higher).
Get this data via API
Financial Data API
EV/EBIT
81.91
YoY
29.67%
Last updated:
The HaTay Pharmaceutical JSC EV/EBIT history
3 Years
10 Years
25 Years
Max
| YEAR | EV/EBIT | YoY |
|---|---|---|
| 81.91 | +29.67% | |
| 63.17 | +3.26% | |
| 61.17 | -39.41% | |
| 100.97 | +76.29% | |
| 57.28 | -10.29% | |
| 63.85 | -9.88% | |
| 70.84 | -3.53% | |
| 73.44 | -22.74% | |
| 95.05 | -28.24% | |
| 132.46 | -18.71% | |
| 162.96 | +22,223.13% | |
| 0.73 | -94.31% | |
| 12.82 | +22.33% | |
| 10.48 | -31.37% | |
| 15.27 | +1.19% | |
| 15.09 | +25.23% | |
| 12.05 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
HaTay Pharmaceutical JSC Valuation
Details
Historical Valuation Multiples
ⓘPrice-to-Earnings Ratio (P/E)
The P/E ratio divides HaTay Pharmaceutical JSC's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.
Price-to-Sales Ratio (P/S)
The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.
Price-to-EBIT Ratio
This ratio relates HaTay Pharmaceutical JSC's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.
How to Use This Chart
This chart plots HaTay Pharmaceutical JSC's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if HaTay Pharmaceutical JSC grows earnings faster than its peers.
HaTay Pharmaceutical JSC Stock analysis
Frequently Asked Questions about HaTay Pharmaceutical JSC stock
EV/EBIT (Enterprise Value to EBIT) of HaTay Pharmaceutical JSC is 81.91 in 2024.
EV/EBIT (Enterprise Value to EBIT) of HaTay Pharmaceutical JSC changed from 63.17 to 81.91, representing a 29.67% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.
The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.
EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes
To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).
A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s HaTay Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Valuation — HaTay Pharmaceutical JSC
All Key Metrics — HaTay Pharmaceutical JSC
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth